Home Dialysis CorMedix signs 5-year agreement with ARC Diaracy (NASDAQ:CRMD)

CorMedix signs 5-year agreement with ARC Diaracy (NASDAQ:CRMD)

0 comments
  • Comedics (Nasdaq:CRMD) announced Monday that it has signed a five-year commercial supply agreement with Florida-based dialysis provider ARC Dialysis for the supply of DefenCath (taurolidine and heparin).
  • CRMD plans to begin commercializing DefenCath for inpatient use on April 15th.
  • press release

You may also like

About Us

Welcome to Daily Transplant News, your trusted source for the latest updates, stories, and information on transplantation and organ donations. We are passionate about sharing the inspiring journeys, groundbreaking research, and invaluable resources surrounding the world of transplantation.

About Us

Welcome to Daily Transplant News, your trusted source for the latest updates, stories, and information on transplantation and organ donations. We are passionate about sharing the inspiring journeys, groundbreaking research, and invaluable resources surrounding the world of transplantation.

Copyright ©️ 2024 Daily Transplant News | All rights reserved.